Amubarvimab/Romlusevimab: First Approval
Author:
- 23 August 2022
- journal article
- research article
- Published by Springer Nature in Drugs
- Vol. 82 (12) , 1327-1331
Abstract
Abstract Amubarvimab 安巴韦单抗注射液/romlusevimab 罗米司韦单抗注射液 is a combination of two neutralizing recombinant human IgG1 monoclonal antibodies (amubarvimab and romlusevimab) against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19). Jointly developed by Brii Biosciences, Tsinghua University and the Third People’s Hospital of Shenzhen, it has been approved (in December 2021) by the National Medical Products Administration of China for the treatment of mild COVID-19 in patients aged ≥ 18 years, and those aged 12–17 years with a bodyweight of ≥ 40 kg (conditional approval) who are at high risk of progressing to severe disease, including hospitalization or death. An Emergency Use Authorization application for amubarvimab/romlusevimab is currently under review in the USA. This article summarizes the milestones in the development of amubarvimab/romlusevimab leading to this first approval for the treatment of COVID-19.This publication has 10 references indexed in Scilit:
- SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2Frontiers in Immunology, 2022
- Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trialThe Lancet Infectious Diseases, 2021
- 520. Pharmacokinetic and Safety Phase 1 Study and Microneutralization Assay Results with BRII-196/BRII-198, a Novel Antibody Cocktail Active Against a Wide Range of SARS-CoV-2 VariantsOpen Forum Infectious Diseases, 2021
- LB2. Safety and Efficacy of Combination SARS-CoV-2 Monoclonal Neutralizing Antibodies (mAb) BRII-196 and BRII-198 in Non-Hospitalized COVID-19 PatientsOpen Forum Infectious Diseases, 2021
- Mechanisms of SARS-CoV-2 entry into cellsNature Reviews Molecular Cell Biology, 2021
- Phase 1 Safety and Pharmacokinetics Studies of BRII-196 and BRII-198, SARS-CoV-2 Spike-Targeting Monoclonal AntibodiesmedRxiv, 2021
- Characteristics of SARS-CoV-2 and COVID-19Nature Reviews Microbiology, 2020
- Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)JAMA, 2020
- COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19Antibody Therapeutics, 2020
- Human neutralizing antibodies elicited by SARS-CoV-2 infectionNature, 2020